GlassScriptPhysician profile
Jonathan Orin Harris
NPI 1841231818
$1,589.07
in general payments reported to CMS, 2019-2025
20 companies · $57.72 in 2025
The $57.72 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $14.18 · 2021: $221 · 2025: $57.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $223.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $212.61 | 2019 | |
| Abbott Laboratories | $189.03 | 2019 | |
| Amgen INC. | $173.31 | 2019-2021 | |
| Biogen, INC. | $164.49 | 2019 | |
| Ucb, INC. | $120.13 | 2019 | |
| Genzyme Corporation | $91.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $89.41 | 2019-2021 | |
| Ge Healthcare | $57.72 | 2025 | |
| Integra Lifesciences Corporation | $53.58 | 2019 | |
| Genentech USA, INC. | $48.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $32.07 | 2019-2020 | |
| Merz North America, INC. | $28.92 | 2019 | |
| Acadia Pharmaceuticals INC | $24.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.06 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.24 | 2019 | |
| Si-Bone, INC. | $15.69 | 2019 | |
| Lilly USA, LLC | $14.17 | 2019 | |
| Boston Scientific Corporation | $11.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.